Procter & Gamble Hygiene and Health Care quarterly results

Q1 FY27 · Apr–Jun 2026

₹ crore	Q1 FY27	Q1 FY26	Change
Revenue	891	937	−4.9%
EBITDA	170	266	−36.1%
EBITDA margin	19.1%	28.4%	−9.3 pts
Profit before tax	170	265	−35.9%
Net profit	126	192	−34.3%
EPS	₹38.90	₹59.17	−34.3%

Every quarter

₹ crore except per share

Tap a line for its trend	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Q2 FY24Sep 2023	Earlier quartersAlpha Plus

Expenses
	891	941	1,262	1,150	937	992	1,248	1,135	932	1,002	1,133	1,138	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	9.4	12.5	12.4	9.9	7.7	19.1	9.7	8.5	7.3	13.6	15.6	15.8
	901	954	1,274	1,160	945	1,011	1,257	1,144	939	1,016	1,149	1,154
	200	171	206	197	164	175	198	194	177	164	215	217
	213	193	217	212	202	210	246	217	232	181	219	223
	−33.2	−7.1	−0.2	36.1	−25.7	9.3	−4.7	10.4	−28.3	−7.1	17.5	5.7
	54.4	56.5	61.7	48.6	48.4	49.4	66.2	60.5	67.1	60.1	54.7	63.7
	0.3	3.1	2.7	3.6	0.1	5.8	6.6	1.9	−0.1	22.4	2.6	1.9
	9.6	9.6	9.5	9.3	9.1	10.4	9.9	11.7	13.4	14.5	14.3	14.3
	287	310	376	372	281	338	371	363	366	347	318	345
	731	736	872	878	680	798	893	858	827	782	841	870
	170	218	402	285	266	210	371	290	118	257	310	285
	160	209	392	275	257	199	361	279	105	243	295	271
Profit
	170	218	402	282	265	213	364	285	112	234	309	284
	170	218	402	282	265	213	364	285	112	234	309	284
	43.9	57.0	102	74.2	71.8	56.8	94.0	80.0	32.9	87.8	79.4	75.3
	−0.5	8.0	−1.5	−2.3	0.8	−0.2	1.5	−6.5	−1.7	−8.2	0.2	−1.6
	43.4	65.0	101	71.9	72.6	56.6	95.5	73.5	31.2	79.6	79.6	73.8
	126	153	301	210	192	156	269	212	81.1	154	229	211
	126	153	301	210	192	156	269	212	81.1	154	229	211
	1.1	0.7	1.2	4.2	−1.8	−1.9	−6.5	1.4	−1.4	3.2	5.6	−1.9
	127	154	303	214	190	154	262	213	79.7	158	234	209
Per share
	₹38.90	₹47.17	₹92.87	₹64.65	₹59.17	₹48.09	₹82.74	₹65.28	₹24.97	₹47.56	₹70.51	₹64.91
	₹38.90	₹47.17	₹92.87	₹64.65	₹59.17	₹48.09	₹82.74	₹65.28	₹24.97	₹47.56	₹70.51	₹64.91
Other comprehensive income — detail
	1.1	0.7	1.2	4.2	−1.8	−1.9	—	—	—	—	—	—
	1.4	0.9	1.6	5.6	−2.4	−2.6	−8.7	1.9	−1.9	4.3	7.5	−2.5
	0.4	0.2	0.4	1.4	−0.6	−0.7	—	—	—	—	—	—
	—	—	—	—	—	—	−2.2	0.5	−0.5	1.1	1.9	−0.6
Per share — as-filed variants
	₹38.90	₹47.17	₹92.87	₹64.65	₹59.17	₹48.09	₹82.74	₹65.28	₹24.97	₹47.56	₹70.51	₹64.91
	₹38.90	₹47.17	₹92.87	₹64.65	₹59.17	₹48.09	₹82.74	₹65.28	₹24.97	₹47.56	₹70.51	₹64.91
Regulatory disclosures — filed alongside, not part of the P&L
	—	757	—	886	—	421	—	—	—	—	—	—
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	511	585	840	705	596	597	808	714	551	664	682	693
	57.3%	62.1%	66.6%	61.3%	63.6%	60.2%	64.8%	62.9%	59.2%	66.3%	60.2%	60.9%
Adjusted (ex-exceptional items) — derived
	170	218	402	282	265	213	364	285	112	234	309	284
	126	153	301	210	192	156	269	212	81.1	154	229	211
	₹38.90	₹47.17	₹92.87	₹64.65	₹59.17	₹48.09	₹82.74	₹65.28	₹24.97	₹47.56	₹70.51	₹64.91

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

PGHH₹6,923.50

Procter & Gamble Hygiene and Health Care Limited

· FMCG & Retail

Annual Quarterly₹ CrorePeersBAJAJCON JHSMcap ₹22,474 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q2 FY24 30/09/2023	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	1,138.4	1,133.4	1,002.2	931.8	1,135.2	1,247.6	991.6	937.0	1,150.2	1,261.9	941.3	891.5
Other Income	15.8	15.6	13.6	7.3	8.5	9.7	19.1	7.7	9.9	12.4	12.5	9.4
Total Income	1,154.1	1,149.0	1,015.8	939.1	1,143.7	1,257.3	1,010.8	944.7	1,160.1	1,274.3	953.8	900.9
Expenses
+ Cost of Materials Consumed	216.5	214.6	164.0	176.9	194.0	197.8	175.4	164.4	197.5	205.5	170.7	200.2
+ Purchases of Stock-in-Trade	222.9	218.9	180.9	231.8	216.8	246.0	210.0	202.5	211.6	216.6	193.2	213.2
+ Changes in Inventories	5.7	17.5	-7.1	-28.3	10.4	-4.7	9.3	-25.7	36.1	-0.2	-7.1	-33.2
+ Employee Benefit Expense	63.7	54.7	60.1	67.1	60.5	66.2	49.4	48.4	48.6	61.7	56.5	54.4
+ Finance Costs	1.9	2.6	22.4	-0.1	1.9	6.6	5.8	0.1	3.6	2.7	3.1	0.3
+ Depreciation & Amortisation	14.3	14.3	14.5	13.4	11.7	9.9	10.4	9.1	9.3	9.5	9.6	9.6
+ Other Expenses	344.6	318.0	347.0	366.0	362.9	371.4	337.9	281.3	371.6	376.5	309.7	286.8
Total Expenses	869.7	840.5	781.8	826.8	858.3	893.2	798.1	680.0	878.3	872.3	735.7	731.3
EBITDA	284.9	309.7	257.3	118.3	290.5	370.9	209.7	266.2	284.8	401.8	218.3	170.1
EBIT	270.6	295.5	242.8	104.9	278.8	361.0	199.3	257.1	275.5	392.3	208.8	160.5
Profit
PBT before Exceptional Items	284.5	308.5	233.9	112.3	285.4	364.1	212.7	264.7	281.8	402.0	218.1	169.6
Pretax Income	284.5	308.5	233.9	112.3	285.4	364.1	212.7	264.7	281.8	402.0	218.1	169.6
+ Current Tax	75.3	79.4	87.8	32.9	80.0	94.0	56.8	71.8	74.2	102.1	57.0	43.9
+ Deferred Tax	-1.6	0.2	-8.2	-1.7	-6.5	1.5	-0.2	0.8	-2.3	-1.5	8.0	-0.5
Tax Expense	73.8	79.6	79.6	31.2	73.5	95.5	56.6	72.6	71.9	100.6	65.0	43.4
Net Income	210.7	228.9	154.4	81.1	211.9	268.6	156.1	192.1	209.9	301.5	153.1	126.3
+ Net Income — Continuing Ops	210.7	228.9	154.4	81.1	211.9	268.6	156.1	192.1	209.9	301.5	153.1	126.3
+ Other Comprehensive Income	-1.9	5.6	3.2	-1.4	1.4	-6.5	-1.9	-1.8	4.2	1.2	0.7	1.1
Total Comprehensive Income	208.8	234.5	157.6	79.7	213.3	262.1	154.2	190.3	214.0	302.7	153.8	127.3
Per Share
Basic EPS	64.91	70.51	47.56	24.97	65.28	82.74	48.09	59.17	64.65	92.87	47.17	38.90
Diluted EPS	64.91	70.51	47.56	24.97	65.28	82.74	48.09	59.17	64.65	92.87	47.17	38.90
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	—	-1.9	-1.8	4.2	1.2	0.7	1.1
+ Items NOT to be Reclassified to P&L	-2.5	7.5	4.3	-1.9	1.9	-8.7	-2.6	-2.4	5.6	1.6	0.9	1.4
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	—	-0.7	-0.6	1.4	0.4	0.2	0.4
+ Tax on Items NOT to be Reclassified — alt tag	-0.6	1.9	1.1	-0.5	0.5	-2.2	—	—	—	—	—	—
Per Share — as-filed variants
Basic EPS — Continuing Operations	64.91	70.51	47.56	24.97	65.28	82.74	48.09	59.17	64.65	92.87	47.17	38.90
Diluted EPS — Continuing Operations	64.91	70.51	47.56	24.97	65.28	82.74	48.09	59.17	64.65	92.87	47.17	38.90
Regulatory Disclosures — filed alongside, not part of the P&L
Related-party Transactions — During the Period	—	—	—	—	—	—	421.0	—	886.2	—	757.2	—
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	693.2	682.5	664.4	551.4	713.9	808.5	596.9	595.9	705.0	839.9	584.5	511.2
Gross Margin %	60.90	60.21	66.30	59.18	62.89	64.80	60.19	63.59	61.29	66.56	62.09	57.35
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	284.5	308.5	233.9	112.3	285.4	364.1	212.7	264.7	281.8	402.0	218.1	169.6
Net Income Adj (tax-effected)	210.7	228.9	154.4	81.1	211.9	268.6	156.1	192.1	209.9	301.5	153.1	126.3
EPS Adj	64.91	70.51	47.56	24.97	65.28	82.74	48.09	59.17	64.65	92.87	47.17	38.90
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00	10.00	10.00	10.00	—	10.00	10.00	10.00	10.00	10.00
Paid Up Equity Capital	32.5	32.5	32.5	32.5	32.5	32.5	32.5	32.5	32.5	32.5	32.5	32.5

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Procter & Gamble Hygiene and Health Care Q2 FY27 results date

Procter & Gamble Hygiene and Health Care (NSE: PGHH) will announce its Q2 FY27 results (July–September 2026) on Thursday, 12 November 2026, according to the board-meeting notice it filed on 25 September 2026. Its latest results are for Q1 FY27 (April–June 2026). Consolidated net profit was ₹126 crore, down 34.3% from ₹192 crore in Q1 FY26 and down 17.5% from ₹153 crore in Q4 FY26. Revenue from operations was ₹891 crore, down 4.9% year on year and down 5.3% from the previous quarter.

Board-meeting notice filed: 25 September 2026
Q2 FY26 results (a year earlier): 6 November 2025
Q1 FY27 results (the latest): 29 July 2026

Latest results: Q1 FY27 (Apr–Jun 2026) · consolidated

Q2 FY27 results date: 12 November 2026Thursday · notice filed 25 Sep
Q1 FY27 net profit: ₹126 Cr−34.3% vs Q1 FY26−17.5% vs Q4 FY26
Q1 FY27 revenue: ₹891 Cr−4.9% vs Q1 FY26−5.3% vs Q4 FY26
Q1 FY27 operating margin: 18.0%−9.4 pts vs Q1 FY26−4.2 pts vs Q4 FY26
Q2 FY26 net profit (a year earlier): ₹210 CrRevenue ₹1,150 Cr
Q1 FY27 EPS (basic): ₹38.90

Questions

When will Procter & Gamble Hygiene and Health Care announce its Q2 FY27 results?

On 12 November 2026, the date of the board meeting called to approve them (notice filed with the exchanges on 25 September 2026). Last year it reported Q2 FY26 on 6 November 2025.

What will Procter & Gamble Hygiene and Health Care's Q2 FY27 results be compared with?

With the same quarter a year earlier, Q2 FY26 (July–September 2025), when consolidated net profit was ₹210 crore and revenue from operations ₹1,150 crore. The latest quarter, Q1 FY27, had a net profit of ₹126 crore and revenue of ₹891 crore.

What were Procter & Gamble Hygiene and Health Care's Q1 FY27 results?

Consolidated net profit was ₹126 crore, down 34.3% from ₹192 crore in Q1 FY26 and down 17.5% from ₹153 crore in Q4 FY26. Revenue from operations was ₹891 crore, down 4.9% year on year and down 5.3% from the previous quarter.

How has Procter & Gamble Hygiene and Health Care's profit changed over the last four quarters?

Net profit by quarter: ₹210 crore in Q2 FY26, ₹301 crore in Q3 FY26, ₹153 crore in Q4 FY26 and ₹126 crore in Q1 FY27. That is ₹791 crore over the four quarters, down 4.6% from ₹829 crore in the four quarters before. Revenue from operations: ₹1,150 crore, ₹1,262 crore, ₹941 crore and ₹891 crore.

What was Procter & Gamble Hygiene and Health Care's net profit in the year to June 2026?

Consolidated net profit was ₹126 crore in the year to June 2026 (July 2025–June 2026), down 34.3% from ₹192 crore in the year to June 2025. It was ₹675 crore in the year to June 2024 and ₹678 crore in the year to June 2023: down 81.4% over three years, an average fall of 42.9% a year.

What was Procter & Gamble Hygiene and Health Care's revenue in the year to June 2026?

Revenue from operations was ₹891 crore in the year to June 2026 (July 2025–June 2026), down 4.9% from ₹937 crore in the year to June 2025. It was ₹4,206 crore in the year to June 2024 and ₹3,918 crore in the year to June 2023: down 77.2% over three years, an average fall of 39.0% a year.

Where do these Procter & Gamble Hygiene and Health Care figures come from?

From Procter & Gamble Hygiene and Health Care's own consolidated results filings to NSE, in ₹ crore as filed; the date from its board-meeting notices.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.